Clinical Trial

Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy

Study acronym: T-DPN
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Tirzepatide is a dual agonist of GLP-1 Receptor and the GIP receptor, producing substantial improvement in glycaemic control, weight reduction and insulin sensitivity. Beyond its metabolic effects, incretin signalling has demonstrated neuroprotective and neurotropic properties, including activation of intracellular pathways that enhance neuronal survival and regeneration. Using tirzapatide for diabetic sensorimotor peripheral neuropathy and assessing with CCM / NCS and BDNF will represent three complementary aspects of nerve regeneration: metabolic control, structural nerve repair and neurotrophic signalling.
Trial Details
NCT Number NCT07706088
Lead Sponsor Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions Neuropathy, Small Fiber, Diabete Mellitus
Enrollment 40 participants
Start Date 2026-07
Primary Completion 2028-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-15